4.3. stone-specific metabolic evaluation pharmacological recurrence prevention. 4.3.1. introduction pharmacological treatment necessary patients high risk stone formation associated systemic conditions. ideal drug halt stone formation, side effects, easy administer. aspects important achieve good compliance. table 4.6 highlights important characteristics commonly used medication. table 4.6: pharmacological substances used stone prevention - characteristics, specifics, dosage. agentrationaledosespecifics side effectsstone typerefalkaline citratesalkalinisationhypocitraturiainhibition ofcalcium oxalatecrystallisation3.25-9.75 g/d(10-30 mmol/d)children:0.1-0.15 g/kg/ddaily dose foralkalinisation dependson urine ph.calcium oxalateuric acidcystine[587-592]allopurinolhyperuricosuriahyperuricaemia100-300 mg/dchildren:1-3 mg/kg/d100 mg isolatedhyperuricosuria.renal insufficiencydemands dosecorrection.contraindicated acute gout pregnancy, breastfeeding.allergies trivial severe forms, xanthine stone formation.calcium oxalateuric acidammonium urate2,8-dihydroxyadenine[557,593-596]calciumenterichyperoxaluriaup 2,000mg/d dependingon oxalateexcretionintake 30 min meals.calcium oxalatecaptoprilcystinuriaactive decrease urinary cystine levels75-150 mgsecond-line option case significant side effects tiopronin.cystinefebuxostathyperuricosuriahyperuricaemia80-120 mg/dcontraindicated acute gout, pregnancy breastfeeding.xanthine stone formation.calcium oxalateuric acidl-methionineacidification600-1,500 mg/dhypercalciuria, bonedemineralisation,systemic acidosis.no long-term therapy.infection stonesammonium uratecalcium phosphatemagnesiumisolatedhypomagnesuriaenterichyperoxaluria200-400 mg/dchildren:6 mg/kg/drenal insufficiencydemands dosecorrection.diarrhoea, chronic alkali losses,hypocitraturia.calcium oxalate(low levelofevidence)sodium bicarbonatealkalinisationhypocitraturia4.5 g/ddaily dose foralkalinisation dependson urine phcalcium oxalateuric acid, cystinepyridoxineprimaryhyperoxaluriainitial dose5 mg/kg/dmax. 20 mg/kg/dsensory peripheral neuropathycalcium oxalatethiazide(hydro-chlorothiazide*)hypercalciuria25-50 mg/dchildren:0.5-1 mg/kg/drisk hypotensiondiabetes,hyperuricaemia,hypokalaemia,hypocitraturia.calcium oxalatecalcium phosphate[583,587-596,598-616]tiopronincystinuriaincrease solubility levelsinitial dose800 mg/davg. 2,000 mg/d**children:initial dose patients > 20kg 15 mg/kg/day.avoid dosages > 50mg/kg/dayrisk forproteinuria.cystine[617-620] * patients hydrochlorothiazide advised get skin checked regular basis higher risk developing non-melanoma skin cancer (nmsc) forms melanoma. patients history skin cancer, indication treatment hydrochlorothiazide thoroughly reviewed [621-623]** information available maximum dose patients may initiated low dose previously reactions tiopronin penicillamine. patients, dosage titrated according frequency stone episodes, side effects, renal function expert supervision close monitoring.